Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Chandler Robinson, Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025, according to a recent SEC Filing. The shares were sold at prices ranging from $40.00 to $40.25, for a total value of $672,020. The sale comes as MNPR shares have surged over 1,000% in the past year, with the stock currently trading at $41.07. According to InvestingPro analysis, analysts maintain a bullish outlook with price targets ranging from $40.08 to $76.00.
On the same day, Robinson also exercised stock options to acquire 16,800 shares of Monopar Therapeutics common stock at a price of $0.005, for a total value of $84.
Following these transactions, Robinson directly owns 73,472 shares of Monopar Therapeutics. Additionally, Robinson may be deemed to share voting and dispositive power over 822,255 shares held by Tactic Pharma LLC. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
In other recent news, Monopar Therapeutics has been added to the Russell 3000 and Russell 2000 indexes, marking a significant recognition of the company’s growth. This inclusion is linked to the development of Monopar’s late-stage drug candidate, ALXN1840, for Wilson disease. ALXN1840, acquired from AstraZeneca (NASDAQ:AZN)’s subsidiary, has shown promising results in phase III clinical trials, demonstrating a threefold increase in copper mobilization from tissues compared to standard care. Despite AstraZeneca halting the development due to earlier phase II data concerns, Monopar plans to seek FDA approval in early 2026, believing in the drug’s potential. Chardan Capital Markets has initiated coverage on Monopar with a buy rating, highlighting the company’s focus on radiopharmaceuticals for improved imaging and therapeutic applications. The company’s inclusion in the Russell indexes is effective for one year, reflecting its standing in the small-cap segment of the U.S. equity market. Monopar’s Chief Financial Officer, Quan Vu, attributes this achievement to the potential of their drug candidate. The company continues its efforts in drug development and aims to secure necessary funds for its clinical and regulatory activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.